Schizophrenia Clinical Trials in Los Angeles

Showing 81-100 of 201 trials

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

NCT03883360

A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of Δ9-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.

Schizophrenia Spectrum DisordersCannabis Use

University of Maryland, BaltimoreStarted Jan 2050

Los Angeles, California, United States • Baltimore, Maryland, United States • Catonsville, Maryland, United States

COMPLETEDPhase 1/2< 1 mile

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539

Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as measured by functional magnetic resonance imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and tolerability of multiple doses of AQW051 in people with schizophrenia.

Schizophrenia

Novartis Pharmaceuticals68 participantsStarted Jan 2009

Los Angeles, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +4 more locations

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

Schizophrenia Trials in Other Cities

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

PACT for Individuals With Serious Mental Illness

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Study of Efficacy of PEAR-004 in Schizophrenia

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Bio-equivalence Study Between SAPHRIS and Asenapine

Clozapine for Cannabis Use in Schizophrenia

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

Other Conditions in Los Angeles